Welcome to CDC Stacks | The cost-effectiveness of routine testing for Lynch syndrome in newly diagnosed patients with colorectal cancer in the United States: corrected estimates - 32326 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
The cost-effectiveness of routine testing for Lynch syndrome in newly diagnosed patients with colorectal cancer in the United States: corrected estimates
Filetype[PDF - 38.66 KB]


Details:
No Related Documents.
You May Also Like:
  1. When is Genomic Testing Cost-Effective? Testing for Lynch Syndrome in Patients with Newly-Diagnosed Colorectal Cancer and Their Relatives
    Personal Author:
    Grosse, Scott D.
    Published:
    2015
    Source:
    Healthcare (Basel). 3(4):860-878.
    Description:
    Varying estimates of the cost-effectiveness of genomic testing applications can reflect differences in study questions, settings, methods and assumptions. This review compares recently published cost-effectiveness analyses of testing strategies for L...
    File Type:
    Filetype[PDF - 231.06 KB]
  2. KRAS testing and first-line treatment among patients diagnosed with metastatic colorectal cancer using population data from ten National Program of Cancer Registries in the United States
    Personal Author:
    Rico, Adriana; Pollack, Lori A.; Thompson, Trevor D.; Hsieh, Mei-chin; Wu, Xiao-Cheng; Karlitz, Jordan J.; West, Dee W.; Rainey, John M.; Chen, Vivien W.;
    Corporate Author:
    on behalf of the Enhancement of NPCR for Comparative Effectiveness Research team
    Published:
    Jan 30 2017
    Source:
    J Cancer Res Ther (Manch). 5(2):7-13.
    Description:
    Background : In 2011, the National Comprehensive Cancer Network (NCCN) recommended KRAS testing for metastatic colorectal cancer (mCRC) patients. Our study assessed KRAS testing prevalence and its association with socio-demographic and clinical facto...
    File Type:
    Filetype[PDF - 130.91 KB]
  3. Cost-Effectiveness of Frequent HIV Testing of High-Risk Populations in the United States
    Personal Author:
    Hutchinson, Angela B.; Farnham, Paul G.; Sansom, Stephanie L.; Yaylali, Emine; Mermin, Jonathan H.;
    Published:
    Mar 1 2016
    Source:
    J Acquir Immune Defic Syndr. 2015; 71(3):323-330.
    Description:
    Purpose: : Data showing a high incidence of HIV infection among men who have sex with men (MSM) who had annual testing suggest that more frequent HIV testing may be warranted. Testing technology is also a consideration given the availability of sensi...
    File Type:
    Filetype[PDF - 232.09 KB]
  4. Coming Soon
    Genetic testing and counseling among patients with newly diagnosed breast cancer
    Personal Author:
    Kurian, Allison W.; Griffith, Kent A.; Hamilton, Ann S.; Ward, Kevin C.; Morrow, Monica; Katz, Steven J.; Jagsi, Reshma;
    Published:
    Feb 07 2017
    Source:
    JAMA. 317(5):531-534.
    Public Access
    Available on:
    February 07, 2018
  5. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States
    Personal Author:
    Shepardson, D.; Marks, S. M.; Chesson, H.; Kerrigan, A.; Holland, D. P.; Scott, N.; Tian, X.; Borisov, A. S.; Shang, N.; Heilig, C. M.; Sterling, T. R.; Villarino, M. E.; Mac Kenzie, W. R.;
    Published:
    Dec 2013
    Source:
    Int J Tuberc Lung Dis. 17(12):1531-1537.
    Description:
    SETTING : A large randomized controlled trial recently showed that for treating latent tuberculous infection (LTBI) in persons at high risk of progression to tuberculosis (TB) disease, a 12-dose regimen of weekly rifapentine plus isoniazid (3HP) admi...
    File Type:
    Filetype[PDF - 910.88 KB]